MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.3400 UNCHANGED
Streaming Delayed Price Updated: 12:17 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3400
Bid (Size) 0.3000 (51,500)
Ask (Size) 0.3450 (5,000)
Prev. Close 0.3400
Today's Range 0.3400 - 0.3400
52wk Range 0.2800 - 1.060
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire

Performance

YTD
-47.7%
-47.7%
1 Month
+11.5%
+11.5%
3 Month
-18.1%
-18.1%
6 Month
-49.3%
-49.3%
1 Year
-67.6%
-67.6%

More News

Read More
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
Via ACCESS Newswire
News headline image
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
Via ACCESS Newswire
News headline image
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
Via ACCESS Newswire
News headline image
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
Via ACCESS Newswire
News headline image
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
Via ACCESS Newswire
News headline image
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
Via ACCESS Newswire
News headline image
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
Via ACCESS Newswire
News headline image
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Via ACCESS Newswire
News headline image
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
Via ACCESS Newswire
News headline image
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
Via ACCESS Newswire
News headline image
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Via ACCESS Newswire
News headline image
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
Via ACCESS Newswire
News headline image
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
Via ACCESS Newswire
News headline image
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
Via ACCESS Newswire
News headline image
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via ACCESS Newswire
News headline image
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
Via ACCESS Newswire
News headline image
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
Via PressReach
Topics Intellectual Property

Frequently Asked Questions

Is BNXT publicly traded?
Yes, BNXT is publicly traded.
What exchange does BNXT trade on?
BNXT trades on the Canadian Securities Exchange
What is the ticker symbol for BNXT?
The ticker symbol for BNXT is BNXT on the Canadian Securities Exchange
What is the current price of BNXT?
The current price of BNXT is 0.3400
When was BNXT last traded?
The last trade of BNXT was at 08/21/26 12:17 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story